Cargando…

IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma

Background: Although a therapeutic effect of dendritic cell (DC)-based immunotherapy, a kind of regenerative medicine, has been recognized in various types of cancer including malignant glioma, it is still impractical because of several unsolved problems. This study is aimed to solve the problems in...

Descripción completa

Detalles Bibliográficos
Autores principales: Akasaki, Yasuharu, Takei, Jun, Yamamoto, Yohei, Tanaka, Toshihide, Kamata, Yuko, Murahashi, Mutsunori, Murayama, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648218/
http://dx.doi.org/10.1093/noajnl/vdab159.042
_version_ 1784610759634845696
author Akasaki, Yasuharu
Takei, Jun
Yamamoto, Yohei
Tanaka, Toshihide
Kamata, Yuko
Murahashi, Mutsunori
Murayama, Yuichi
author_facet Akasaki, Yasuharu
Takei, Jun
Yamamoto, Yohei
Tanaka, Toshihide
Kamata, Yuko
Murahashi, Mutsunori
Murayama, Yuichi
author_sort Akasaki, Yasuharu
collection PubMed
description Background: Although a therapeutic effect of dendritic cell (DC)-based immunotherapy, a kind of regenerative medicine, has been recognized in various types of cancer including malignant glioma, it is still impractical because of several unsolved problems. This study is aimed to solve the problems in regenerative medicine through a clinical trial of immunotherapy using fusions of DCs and glioma cells (GCs) against malignant glioma, and to put it into practical use. Methods: Primary cultured GCs and glioma stem cells (GSCs) were generated from surgical specimens of patient. DCs were generated from PBMC of same patient, and were fused with GCs and GSCs. The entire process of cell production must be performed by pairs of two cell-culture operators in a dedicated cell processing facility. We developed a remote cell-observation system for reducing hands work of operators. As a project to establish a preservation method, cryopreservation of glioma tissues, GCs/GSCs, DCs and fusion cells followed by their viability examination. Results: The remote cell-observation system worked stable in morphological observation and cell-counting for adhesion cells. A growth curve was also automatically and accurately created. Although a morphological observation of floating cells such as GSCs and DCs was possible, there was some error in counting of those cells. A project to establish a preservation method is currently underway, including the development of storage containers and storage liquids. Conclusions: Although the remote cell-observation system required some modifications at the observation site, depth of focus, etc. for floating cells, there was no problem in accuracy for adhesion cells compared with operator’s observation. This system, which can be easily installed at low cost, seemed to be helpful for practical use of regenerative medical products including this therapy. We are working on a project to establish a stable transportation and preservation method for prevalence of this treatment.
format Online
Article
Text
id pubmed-8648218
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86482182021-12-07 IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma Akasaki, Yasuharu Takei, Jun Yamamoto, Yohei Tanaka, Toshihide Kamata, Yuko Murahashi, Mutsunori Murayama, Yuichi Neurooncol Adv Supplement Abstracts Background: Although a therapeutic effect of dendritic cell (DC)-based immunotherapy, a kind of regenerative medicine, has been recognized in various types of cancer including malignant glioma, it is still impractical because of several unsolved problems. This study is aimed to solve the problems in regenerative medicine through a clinical trial of immunotherapy using fusions of DCs and glioma cells (GCs) against malignant glioma, and to put it into practical use. Methods: Primary cultured GCs and glioma stem cells (GSCs) were generated from surgical specimens of patient. DCs were generated from PBMC of same patient, and were fused with GCs and GSCs. The entire process of cell production must be performed by pairs of two cell-culture operators in a dedicated cell processing facility. We developed a remote cell-observation system for reducing hands work of operators. As a project to establish a preservation method, cryopreservation of glioma tissues, GCs/GSCs, DCs and fusion cells followed by their viability examination. Results: The remote cell-observation system worked stable in morphological observation and cell-counting for adhesion cells. A growth curve was also automatically and accurately created. Although a morphological observation of floating cells such as GSCs and DCs was possible, there was some error in counting of those cells. A project to establish a preservation method is currently underway, including the development of storage containers and storage liquids. Conclusions: Although the remote cell-observation system required some modifications at the observation site, depth of focus, etc. for floating cells, there was no problem in accuracy for adhesion cells compared with operator’s observation. This system, which can be easily installed at low cost, seemed to be helpful for practical use of regenerative medical products including this therapy. We are working on a project to establish a stable transportation and preservation method for prevalence of this treatment. Oxford University Press 2021-12-06 /pmc/articles/PMC8648218/ http://dx.doi.org/10.1093/noajnl/vdab159.042 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Akasaki, Yasuharu
Takei, Jun
Yamamoto, Yohei
Tanaka, Toshihide
Kamata, Yuko
Murahashi, Mutsunori
Murayama, Yuichi
IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
title IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
title_full IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
title_fullStr IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
title_full_unstemmed IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
title_short IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
title_sort imt-1 a translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648218/
http://dx.doi.org/10.1093/noajnl/vdab159.042
work_keys_str_mv AT akasakiyasuharu imt1atranslationalresearchforpracticaluseofdendriticcellbasedimmunotherapyagainstmalignantglioma
AT takeijun imt1atranslationalresearchforpracticaluseofdendriticcellbasedimmunotherapyagainstmalignantglioma
AT yamamotoyohei imt1atranslationalresearchforpracticaluseofdendriticcellbasedimmunotherapyagainstmalignantglioma
AT tanakatoshihide imt1atranslationalresearchforpracticaluseofdendriticcellbasedimmunotherapyagainstmalignantglioma
AT kamatayuko imt1atranslationalresearchforpracticaluseofdendriticcellbasedimmunotherapyagainstmalignantglioma
AT murahashimutsunori imt1atranslationalresearchforpracticaluseofdendriticcellbasedimmunotherapyagainstmalignantglioma
AT murayamayuichi imt1atranslationalresearchforpracticaluseofdendriticcellbasedimmunotherapyagainstmalignantglioma